Pulse Biosciences, Inc. (PLSE) Company Overview

What does Pulse Biosciences do?

Pulse Biosciences, Inc. is a Nasdaq-listed medical-device developer focused on a proprietary energy modality called Nano-pulse Stimulation, or NPS. In tissue-ablation applications the company also calls the modality nanosecond pulsed-field ablation, or nsPFA. The technology sends electrical pulses lasting less than one millionth of a second into targeted tissue, aiming to disrupt cells without relying on the thermal injury used by conventional radiofrequency or cryoablation. The company’s 2025 Form 10-K frames Pulse as a novel ablation company rather than a mature commercial medtech manufacturer.

Which products define the current portfolio?

Pulse therefore sits between a pre-revenue biotechnology profile and an early-stage medtech profile. It has one cleared product generating modest revenue, but most of the economic value still depends on clinical evidence, regulatory authorizations, physician adoption, manufacturing scale-up, and the eventual economics of recurring disposable use.

How does Pulse Biosciences make money?

The intended model is a classic medtech “platform plus consumables” structure. Hospitals or treatment centers use the proprietary nPulse console, while physicians purchase procedure-specific disposable applicators such as catheters, clamps, or needle electrodes. If clinical adoption develops, recurring disposable revenue should matter more than console placements because each procedure requires a new sterile device. At present, however, reported revenue comes only from the limited market release of Vybrance; the cardiac programs remain development-stage assets.

Which revenue stream matters most?

Today, Vybrance is the only product contributing revenue, but it is not yet large enough to establish a normalized gross margin. Q1 2026 product revenue was $401,000 and cost of product revenue was $370,000, implying roughly $31,000 of reported gross profit and a gross margin near 7.7%. That figure should not be treated as mature unit economics: launch volumes are low, manufacturing absorption is limited, and commercial support costs are still embedded elsewhere in operating expenses.

What do the latest financial results show?

The quarter ended March 31, 2026 showed a company beginning to record commercial sales while still consuming capital at a development-stage rate. Revenue increased from zero in Q1 2025 to $0.4 million in Q1 2026. R&D rose by $2.3 million year over year, while SG&A fell by $1.1 million. The net loss widened by $1.8 million to $18.6 million.

How does Q1 compare with the 2025 annual baseline?

FY2025 product revenue was $0.35 million, cost of product revenue was $0.54 million, R&D was $44.7 million, SG&A was $32.0 million, and net loss was $72.8 million. The first quarter of 2026 therefore represented about 28% of the prior full year’s R&D spend and about 26% of the prior full year’s net loss. Those ratios suggest the development cadence remained elevated rather than stepping down after the 2025 trial build-out.

How strong is Pulse Biosciences’ balance sheet?

As of March 31, 2026, Pulse held $68.3 million in cash and cash equivalents, down from $80.7 million at December 31, 2025. Total current assets were $71.1 million, current liabilities were $9.8 million, and total liabilities were $15.3 million. The company reported no conventional funded debt in the balance sheet table, but it did carry $7.2 million of current and long-term lease liabilities. The resulting current ratio was approximately 7.3 times, which indicates ample near-term liquidity relative to recorded current obligations.

What does cash burn imply for financing?

Q1 2026 operating cash use was $14.6 million, versus $13.5 million in Q1 2025. Investing cash use was less than $0.1 million, so operating burn is a reasonable near-term proxy for cash consumption. A simple annualization of the Q1 figure would approach $58 million, although actual trial timing, working capital, and financing activity can make quarterly burn uneven. Management stated that existing resources plus proceeds received from a May 2026 at-the-market sale were sufficient for at least twelve months from the filing date, while also saying it planned to raise additional capital in the near future.

Which strategic turning points still shape the company?

Pulse’s history is best understood as a sequence of technology and market-focus decisions rather than as a conventional revenue-growth story. The important question is not how many years the company has existed, but how each pivot changed the probability, cost, and size of the commercial opportunity.

1. 2014
   The business was incorporated as Electroblate, establishing the corporate vehicle for nanosecond electrical-pulse technology.
2. 2015
   The company adopted the Pulse Biosciences name, aligning its identity with the core energy platform.
3. 2017
   Robert W. Duggan joined the board and later became the controlling shareholder, creating an unusually concentrated governance and financing structure.
4. 2022
   Management redirected primary effort toward atrial fibrillation, moving from dermatology toward a larger, clinically demanding cardiac-ablation market.
5. 2024
   Vybrance received two FDA 510(k) clearances, while the Cardiac Surgery System received Breakthrough Device Designation; these milestones are described in the company’s official annual report.
6. 2025
   Vybrance generated its first commercial sale, and the PRECISE BTN study began to build evidence in benign thyroid nodules.
7. 2026
   The company sharpened its focus on electrophysiology catheter development after encouraging European feasibility data and continued raising capital through equity-linked channels.

Why was the 2022 cardiac pivot so important?

Atrial fibrillation is a far larger commercial target than the company’s original dermatology applications, but the pivot also raised the clinical, regulatory, competitive, and funding stakes. Pulse cited approximately 1.9 million U.S. patients diagnosed annually and an electrophysiology addressable market above $3.0 billion. Those are opportunity indicators, not guaranteed sales. Success requires compelling head-to-head procedural value in a field served by large cardiovascular-device companies with established sales forces, training systems, and installed capital equipment.

What gives Pulse Biosciences a competitive advantage?

The proposed advantage is technological differentiation. Conventional thermal ablation destroys tissue through heat or freezing, while Pulse’s nsPFA is designed to use ultrashort electrical pulses to cause cell death without thermal necrosis. In principle, a nonthermal mechanism may support precise lesions, less collateral damage to surrounding structures, and new device geometries. The value of that differentiation, however, must be demonstrated in reproducible clinical outcomes and practical workflows.

Who are the main competitors?

In electrophysiology, Pulse competes for physician attention and hospital budgets against established platforms from companies such as Boston Scientific, Johnson & Johnson MedTech, Medtronic, and Abbott, as well as other pulsed-field-ablation developers. The company also faces procedural substitutes: antiarrhythmic drugs, thermal ablation, hybrid surgical approaches, and competing PFA systems. Rivalry is therefore not only about lesion technology; it includes mapping integration, catheter handling, training, workflow time, clinical evidence, service support, capital-equipment placement, and reimbursement.

Who owns Pulse Biosciences stock, and why does control matter?

Ownership is one of the most distinctive parts of the PLSE profile. According to the 2026 proxy statement, Robert W. Duggan beneficially owned 49,037,818 shares, including securities exercisable within 60 days, equal to 71.6% of the outstanding class as of March 31, 2026. Directors and executive officers as a group beneficially owned 51,975,515 shares, or 74.0%.

How should researchers interpret concentrated control?

Concentration can support long-term decision-making because management does not need to optimize every quarter for dispersed shareholders. Duggan has also provided strategic and financing support over time. The trade-off is that minority investors have limited practical ability to change board composition, strategic direction, executive incentives, or financing choices. The 2025 10-K also warned that approximately 72% insider-affiliate ownership reduces trading liquidity and can amplify share-price volatility.

The board nominated seven directors for the June 11, 2026 annual meeting, with Paul A. LaViolette serving as CEO, president, and co-chairman, and Duggan serving as co-chairman. The structure combines operating leadership with a controlling capital sponsor. Investors should therefore assess not only whether the technology works, but whether capital allocation and related-party arrangements remain aligned with minority shareholders.

What opportunities and risks could change the story?

The upside case is built around successful cardiac clinical development, efficient regulatory engagement, and eventual recurring disposable economics. The downside case centers on trial uncertainty, commercialization delays, competitive response, and repeated equity issuance. The company’s own filings emphasize that even Breakthrough Device or TAP participation does not relax FDA safety-and-effectiveness standards.

Why is dilution a central financial risk?

Pulse had 68.2 million shares outstanding at March 31, 2026 and 69.2 million as of May 12, 2026. It also maintained a $60 million ATM program with approximately $46.7 million available at the Q1 filing date and a separate $200 million shelf registration. These facilities improve financing flexibility but make per-share value sensitive to issuance price and total capital required before commercialization. In June 2026, the company announced redemption of the remaining 200% rights-offering warrants. It had received $60 million from the 2024 rights offering and another $63.7 million from exercises of the two warrant tranches through the announcement date, with up to $2.1 million of additional gross proceeds possible before the July 13 redemption deadline. The warrant redemption announcement therefore reduced one overhang while adding cash and shares.

Which KPIs matter most for valuation?

A conventional DCF based on near-term sales is fragile because current revenue is too small and the cardiac programs are not yet commercial. A more defensible framework separates the company into probability-weighted programs, estimates future procedure economics only after regulatory milestones, and explicitly models dilution. The discount rate must reflect clinical, regulatory, commercialization, and financing risk rather than simply using a mature-medtech peer average.

What should a model include?

Which near-term milestones carry the most information?

The highest-information events are catheter trial updates, longer-duration outcome data, FDA pathway clarity, Cardiac Surgery System progress under the TAP program, Vybrance procedure growth, and quarterly cash burn. Students should distinguish a milestone that improves probability of technical success from one that merely extends financing runway. A capital raise can lower insolvency risk while still reducing per-share value; a small clinical dataset can raise enthusiasm while leaving pivotal-study risk unresolved.

What is the key takeaway from Pulse Biosciences analysis?

Pulse Biosciences is an early-commercial, high-R&D medical-device company whose value depends primarily on whether nsPFA can become a differentiated cardiac-ablation platform. The company has genuine assets: proprietary nanosecond pulse technology, a multi-applicator console architecture, FDA-cleared Vybrance products, Breakthrough Device and TAP engagement for cardiac surgery, and early catheter data strong enough to justify a sharper strategic focus. It also has substantial liquidity relative to current liabilities and a controlling shareholder who has historically supported financing.

The constraints are equally material. Q1 2026 revenue was only $0.4 million, the quarterly net loss was $18.6 million, operating cash use was $14.6 million, and the accumulated deficit reached $481.9 million. Large medtech competitors possess deeper sales infrastructure and broader hospital relationships. Regulatory designations do not guarantee approval, early feasibility outcomes may not replicate, reimbursement is not automatic, and future equity issuance can materially alter per-share economics.